nodes	percent_of_prediction	percent_of_DWPC	metapath
Estropipate—SLC22A1—Cytarabine—lymphatic system cancer	0.299	0.389	CbGbCtD
Estropipate—CYP1A2—Carmustine—lymphatic system cancer	0.153	0.2	CbGbCtD
Estropipate—CYP2C9—Teniposide—lymphatic system cancer	0.0929	0.121	CbGbCtD
Estropipate—CYP3A4—Cytarabine—lymphatic system cancer	0.0548	0.0714	CbGbCtD
Estropipate—CYP3A4—Teniposide—lymphatic system cancer	0.054	0.0703	CbGbCtD
Estropipate—ALB—Methotrexate—lymphatic system cancer	0.0502	0.0654	CbGbCtD
Estropipate—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0378	0.0492	CbGbCtD
Estropipate—CYP3A4—Vincristine—lymphatic system cancer	0.026	0.0339	CbGbCtD
Estropipate—Embolism—Methotrexate—lymphatic system cancer	0.00109	0.00472	CcSEcCtD
Estropipate—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00106	0.00456	CcSEcCtD
Estropipate—Alopecia—Fludarabine—lymphatic system cancer	0.00105	0.00453	CcSEcCtD
Estropipate—Pain in extremity—Vincristine—lymphatic system cancer	0.00105	0.00453	CcSEcCtD
Estropipate—Cyst—Methotrexate—lymphatic system cancer	0.00105	0.00453	CcSEcCtD
Estropipate—Malnutrition—Fludarabine—lymphatic system cancer	0.00104	0.00446	CcSEcCtD
Estropipate—Oedema—Teniposide—lymphatic system cancer	0.000962	0.00414	CcSEcCtD
Estropipate—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000962	0.00414	CcSEcCtD
Estropipate—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.000958	0.00413	CcSEcCtD
Estropipate—Infection—Teniposide—lymphatic system cancer	0.000956	0.00412	CcSEcCtD
Estropipate—Myocardial infarction—Bleomycin—lymphatic system cancer	0.000953	0.0041	CcSEcCtD
Estropipate—Pruritus—Mechlorethamine—lymphatic system cancer	0.000923	0.00398	CcSEcCtD
Estropipate—Cough—Fludarabine—lymphatic system cancer	0.000904	0.00389	CcSEcCtD
Estropipate—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000893	0.00385	CcSEcCtD
Estropipate—Myalgia—Fludarabine—lymphatic system cancer	0.000882	0.0038	CcSEcCtD
Estropipate—Arthralgia—Fludarabine—lymphatic system cancer	0.000882	0.0038	CcSEcCtD
Estropipate—Hyperglycaemia—Carmustine—lymphatic system cancer	0.000859	0.0037	CcSEcCtD
Estropipate—Dysuria—Vincristine—lymphatic system cancer	0.00085	0.00366	CcSEcCtD
Estropipate—Depression—Carmustine—lymphatic system cancer	0.000846	0.00364	CcSEcCtD
Estropipate—Oedema—Fludarabine—lymphatic system cancer	0.000846	0.00364	CcSEcCtD
Estropipate—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000846	0.00364	CcSEcCtD
Estropipate—Infection—Fludarabine—lymphatic system cancer	0.00084	0.00362	CcSEcCtD
Estropipate—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.000832	0.00358	CcSEcCtD
Estropipate—Vomiting—Mechlorethamine—lymphatic system cancer	0.00083	0.00357	CcSEcCtD
Estropipate—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000829	0.00357	CcSEcCtD
Estropipate—Rash—Mechlorethamine—lymphatic system cancer	0.000823	0.00354	CcSEcCtD
Estropipate—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.000822	0.00354	CcSEcCtD
Estropipate—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000822	0.00354	CcSEcCtD
Estropipate—Depression—Vincristine—lymphatic system cancer	0.000808	0.00348	CcSEcCtD
Estropipate—Weight increased—Mitoxantrone—lymphatic system cancer	0.000805	0.00347	CcSEcCtD
Estropipate—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000799	0.00344	CcSEcCtD
Estropipate—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.000798	0.00344	CcSEcCtD
Estropipate—Myocardial infarction—Vincristine—lymphatic system cancer	0.000794	0.00342	CcSEcCtD
Estropipate—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.000794	0.00342	CcSEcCtD
Estropipate—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000787	0.00339	CcSEcCtD
Estropipate—Bone disorder—Methotrexate—lymphatic system cancer	0.000778	0.00335	CcSEcCtD
Estropipate—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000778	0.00335	CcSEcCtD
Estropipate—Nausea—Mechlorethamine—lymphatic system cancer	0.000775	0.00334	CcSEcCtD
Estropipate—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000773	0.00333	CcSEcCtD
Estropipate—Alopecia—Bleomycin—lymphatic system cancer	0.000771	0.00332	CcSEcCtD
Estropipate—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00077	0.00332	CcSEcCtD
Estropipate—Urticaria—Teniposide—lymphatic system cancer	0.000764	0.00329	CcSEcCtD
Estropipate—Abdominal pain—Teniposide—lymphatic system cancer	0.000761	0.00328	CcSEcCtD
Estropipate—Body temperature increased—Teniposide—lymphatic system cancer	0.000761	0.00328	CcSEcCtD
Estropipate—Erythema—Bleomycin—lymphatic system cancer	0.00076	0.00327	CcSEcCtD
Estropipate—Paraesthesia—Fludarabine—lymphatic system cancer	0.000759	0.00327	CcSEcCtD
Estropipate—Oedema peripheral—Carmustine—lymphatic system cancer	0.00075	0.00323	CcSEcCtD
Estropipate—Dyspepsia—Fludarabine—lymphatic system cancer	0.000744	0.00321	CcSEcCtD
Estropipate—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00074	0.00319	CcSEcCtD
Estropipate—Visual impairment—Carmustine—lymphatic system cancer	0.000734	0.00316	CcSEcCtD
Estropipate—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00073	0.00314	CcSEcCtD
Estropipate—Fatigue—Fludarabine—lymphatic system cancer	0.000729	0.00314	CcSEcCtD
Estropipate—Inflammation—Methotrexate—lymphatic system cancer	0.000724	0.00312	CcSEcCtD
Estropipate—Pain—Fludarabine—lymphatic system cancer	0.000723	0.00312	CcSEcCtD
Estropipate—Constipation—Fludarabine—lymphatic system cancer	0.000723	0.00312	CcSEcCtD
Estropipate—Eye disorder—Carmustine—lymphatic system cancer	0.000712	0.00307	CcSEcCtD
Estropipate—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00071	0.00306	CcSEcCtD
Estropipate—Hypersensitivity—Teniposide—lymphatic system cancer	0.000709	0.00305	CcSEcCtD
Estropipate—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000703	0.00303	CcSEcCtD
Estropipate—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.000703	0.00303	CcSEcCtD
Estropipate—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.000703	0.00303	CcSEcCtD
Estropipate—Asthenia—Teniposide—lymphatic system cancer	0.00069	0.00297	CcSEcCtD
Estropipate—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.000686	0.00296	CcSEcCtD
Estropipate—Pruritus—Teniposide—lymphatic system cancer	0.000681	0.00293	CcSEcCtD
Estropipate—Cystitis—Methotrexate—lymphatic system cancer	0.000679	0.00292	CcSEcCtD
Estropipate—Cardiac disorder—Vincristine—lymphatic system cancer	0.000675	0.00291	CcSEcCtD
Estropipate—Alopecia—Carmustine—lymphatic system cancer	0.000673	0.0029	CcSEcCtD
Estropipate—Body temperature increased—Fludarabine—lymphatic system cancer	0.000669	0.00288	CcSEcCtD
Estropipate—Mental disorder—Carmustine—lymphatic system cancer	0.000667	0.00287	CcSEcCtD
Estropipate—Vaginal infection—Methotrexate—lymphatic system cancer	0.000663	0.00286	CcSEcCtD
Estropipate—Malnutrition—Carmustine—lymphatic system cancer	0.000663	0.00286	CcSEcCtD
Estropipate—Erythema—Carmustine—lymphatic system cancer	0.000663	0.00286	CcSEcCtD
Estropipate—Cough—Bleomycin—lymphatic system cancer	0.000663	0.00286	CcSEcCtD
Estropipate—Angiopathy—Vincristine—lymphatic system cancer	0.00066	0.00284	CcSEcCtD
Estropipate—Diarrhoea—Teniposide—lymphatic system cancer	0.000658	0.00284	CcSEcCtD
Estropipate—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000655	0.00282	CcSEcCtD
Estropipate—Myalgia—Bleomycin—lymphatic system cancer	0.000647	0.00279	CcSEcCtD
Estropipate—Alopecia—Vincristine—lymphatic system cancer	0.000643	0.00277	CcSEcCtD
Estropipate—Back pain—Carmustine—lymphatic system cancer	0.000641	0.00276	CcSEcCtD
Estropipate—Mental disorder—Vincristine—lymphatic system cancer	0.000637	0.00274	CcSEcCtD
Estropipate—Bladder pain—Methotrexate—lymphatic system cancer	0.000635	0.00274	CcSEcCtD
Estropipate—Neoplasm—Methotrexate—lymphatic system cancer	0.000635	0.00274	CcSEcCtD
Estropipate—Alopecia—Mitoxantrone—lymphatic system cancer	0.000626	0.0027	CcSEcCtD
Estropipate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000623	0.00268	CcSEcCtD
Estropipate—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00062	0.00267	CcSEcCtD
Estropipate—Oedema—Bleomycin—lymphatic system cancer	0.00062	0.00267	CcSEcCtD
Estropipate—Erythema—Mitoxantrone—lymphatic system cancer	0.000617	0.00266	CcSEcCtD
Estropipate—Infection—Bleomycin—lymphatic system cancer	0.000616	0.00265	CcSEcCtD
Estropipate—Back pain—Vincristine—lymphatic system cancer	0.000612	0.00264	CcSEcCtD
Estropipate—Vomiting—Teniposide—lymphatic system cancer	0.000612	0.00264	CcSEcCtD
Estropipate—Asthenia—Fludarabine—lymphatic system cancer	0.000607	0.00261	CcSEcCtD
Estropipate—Rash—Teniposide—lymphatic system cancer	0.000607	0.00261	CcSEcCtD
Estropipate—Dermatitis—Teniposide—lymphatic system cancer	0.000606	0.00261	CcSEcCtD
Estropipate—Headache—Teniposide—lymphatic system cancer	0.000603	0.0026	CcSEcCtD
Estropipate—Pruritus—Fludarabine—lymphatic system cancer	0.000598	0.00258	CcSEcCtD
Estropipate—Back pain—Mitoxantrone—lymphatic system cancer	0.000596	0.00257	CcSEcCtD
Estropipate—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000589	0.00254	CcSEcCtD
Estropipate—Diarrhoea—Fludarabine—lymphatic system cancer	0.000579	0.00249	CcSEcCtD
Estropipate—Nausea—Teniposide—lymphatic system cancer	0.000572	0.00246	CcSEcCtD
Estropipate—Vertigo—Vincristine—lymphatic system cancer	0.000569	0.00245	CcSEcCtD
Estropipate—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000565	0.00243	CcSEcCtD
Estropipate—Myalgia—Carmustine—lymphatic system cancer	0.000565	0.00243	CcSEcCtD
Estropipate—Anxiety—Carmustine—lymphatic system cancer	0.000563	0.00242	CcSEcCtD
Estropipate—Paraesthesia—Bleomycin—lymphatic system cancer	0.000557	0.0024	CcSEcCtD
Estropipate—Oedema—Carmustine—lymphatic system cancer	0.000541	0.00233	CcSEcCtD
Estropipate—Myalgia—Vincristine—lymphatic system cancer	0.000539	0.00232	CcSEcCtD
Estropipate—Visual disturbance—Methotrexate—lymphatic system cancer	0.000538	0.00232	CcSEcCtD
Estropipate—Cough—Mitoxantrone—lymphatic system cancer	0.000538	0.00232	CcSEcCtD
Estropipate—Infection—Carmustine—lymphatic system cancer	0.000538	0.00232	CcSEcCtD
Estropipate—Vomiting—Fludarabine—lymphatic system cancer	0.000538	0.00232	CcSEcCtD
Estropipate—Rash—Fludarabine—lymphatic system cancer	0.000533	0.0023	CcSEcCtD
Estropipate—Dermatitis—Fludarabine—lymphatic system cancer	0.000533	0.00229	CcSEcCtD
Estropipate—Pain—Bleomycin—lymphatic system cancer	0.00053	0.00228	CcSEcCtD
Estropipate—Headache—Fludarabine—lymphatic system cancer	0.00053	0.00228	CcSEcCtD
Estropipate—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000527	0.00227	CcSEcCtD
Estropipate—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000525	0.00226	CcSEcCtD
Estropipate—Myalgia—Mitoxantrone—lymphatic system cancer	0.000525	0.00226	CcSEcCtD
Estropipate—Anxiety—Mitoxantrone—lymphatic system cancer	0.000523	0.00225	CcSEcCtD
Estropipate—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000521	0.00224	CcSEcCtD
Estropipate—Oedema—Vincristine—lymphatic system cancer	0.000517	0.00223	CcSEcCtD
Estropipate—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000517	0.00223	CcSEcCtD
Estropipate—Infection—Vincristine—lymphatic system cancer	0.000513	0.00221	CcSEcCtD
Estropipate—Nervous system disorder—Vincristine—lymphatic system cancer	0.000507	0.00218	CcSEcCtD
Estropipate—Oedema—Mitoxantrone—lymphatic system cancer	0.000503	0.00217	CcSEcCtD
Estropipate—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000503	0.00217	CcSEcCtD
Estropipate—Nausea—Fludarabine—lymphatic system cancer	0.000502	0.00216	CcSEcCtD
Estropipate—Infection—Mitoxantrone—lymphatic system cancer	0.0005	0.00215	CcSEcCtD
Estropipate—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000493	0.00212	CcSEcCtD
Estropipate—Urticaria—Bleomycin—lymphatic system cancer	0.000493	0.00212	CcSEcCtD
Estropipate—Body temperature increased—Bleomycin—lymphatic system cancer	0.00049	0.00211	CcSEcCtD
Estropipate—Insomnia—Carmustine—lymphatic system cancer	0.00049	0.00211	CcSEcCtD
Estropipate—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000489	0.00211	CcSEcCtD
Estropipate—Irritability—Methotrexate—lymphatic system cancer	0.000487	0.0021	CcSEcCtD
Estropipate—Paraesthesia—Carmustine—lymphatic system cancer	0.000486	0.00209	CcSEcCtD
Estropipate—Mood swings—Methotrexate—lymphatic system cancer	0.000483	0.00208	CcSEcCtD
Estropipate—Somnolence—Carmustine—lymphatic system cancer	0.000481	0.00207	CcSEcCtD
Estropipate—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000471	0.00203	CcSEcCtD
Estropipate—Insomnia—Vincristine—lymphatic system cancer	0.000467	0.00201	CcSEcCtD
Estropipate—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000467	0.00201	CcSEcCtD
Estropipate—Paraesthesia—Vincristine—lymphatic system cancer	0.000464	0.002	CcSEcCtD
Estropipate—Pain—Carmustine—lymphatic system cancer	0.000463	0.00199	CcSEcCtD
Estropipate—Constipation—Carmustine—lymphatic system cancer	0.000463	0.00199	CcSEcCtD
Estropipate—Breast disorder—Methotrexate—lymphatic system cancer	0.000461	0.00199	CcSEcCtD
Estropipate—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000458	0.00197	CcSEcCtD
Estropipate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000457	0.00197	CcSEcCtD
Estropipate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000452	0.00195	CcSEcCtD
Estropipate—Somnolence—Mitoxantrone—lymphatic system cancer	0.000447	0.00193	CcSEcCtD
Estropipate—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000446	0.00192	CcSEcCtD
Estropipate—Fatigue—Vincristine—lymphatic system cancer	0.000445	0.00192	CcSEcCtD
Estropipate—Asthenia—Bleomycin—lymphatic system cancer	0.000445	0.00192	CcSEcCtD
Estropipate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000443	0.00191	CcSEcCtD
Estropipate—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000443	0.00191	CcSEcCtD
Estropipate—Pain—Vincristine—lymphatic system cancer	0.000442	0.0019	CcSEcCtD
Estropipate—Constipation—Vincristine—lymphatic system cancer	0.000442	0.0019	CcSEcCtD
Estropipate—Asthma—Methotrexate—lymphatic system cancer	0.000441	0.0019	CcSEcCtD
Estropipate—Pruritus—Bleomycin—lymphatic system cancer	0.000439	0.00189	CcSEcCtD
Estropipate—Fatigue—Mitoxantrone—lymphatic system cancer	0.000434	0.00187	CcSEcCtD
Estropipate—Pancreatitis—Methotrexate—lymphatic system cancer	0.000432	0.00186	CcSEcCtD
Estropipate—Constipation—Mitoxantrone—lymphatic system cancer	0.00043	0.00185	CcSEcCtD
Estropipate—Pain—Mitoxantrone—lymphatic system cancer	0.00043	0.00185	CcSEcCtD
Estropipate—Abdominal pain—Carmustine—lymphatic system cancer	0.000428	0.00184	CcSEcCtD
Estropipate—Body temperature increased—Carmustine—lymphatic system cancer	0.000428	0.00184	CcSEcCtD
Estropipate—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000423	0.00182	CcSEcCtD
Estropipate—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000422	0.00182	CcSEcCtD
Estropipate—Dysuria—Methotrexate—lymphatic system cancer	0.000412	0.00178	CcSEcCtD
Estropipate—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000411	0.00177	CcSEcCtD
Estropipate—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00041	0.00176	CcSEcCtD
Estropipate—Abdominal pain—Vincristine—lymphatic system cancer	0.000408	0.00176	CcSEcCtD
Estropipate—Body temperature increased—Vincristine—lymphatic system cancer	0.000408	0.00176	CcSEcCtD
Estropipate—Urticaria—Mitoxantrone—lymphatic system cancer	0.0004	0.00172	CcSEcCtD
Estropipate—Hypersensitivity—Carmustine—lymphatic system cancer	0.000399	0.00172	CcSEcCtD
Estropipate—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000398	0.00171	CcSEcCtD
Estropipate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000398	0.00171	CcSEcCtD
Estropipate—Vomiting—Bleomycin—lymphatic system cancer	0.000394	0.0017	CcSEcCtD
Estropipate—Infestation NOS—Methotrexate—lymphatic system cancer	0.000393	0.00169	CcSEcCtD
Estropipate—Infestation—Methotrexate—lymphatic system cancer	0.000393	0.00169	CcSEcCtD
Estropipate—Depression—Methotrexate—lymphatic system cancer	0.000392	0.00169	CcSEcCtD
Estropipate—Rash—Bleomycin—lymphatic system cancer	0.000391	0.00168	CcSEcCtD
Estropipate—Dermatitis—Bleomycin—lymphatic system cancer	0.000391	0.00168	CcSEcCtD
Estropipate—Asthenia—Carmustine—lymphatic system cancer	0.000388	0.00167	CcSEcCtD
Estropipate—Hypersensitivity—Vincristine—lymphatic system cancer	0.000381	0.00164	CcSEcCtD
Estropipate—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000372	0.0016	CcSEcCtD
Estropipate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000371	0.0016	CcSEcCtD
Estropipate—Asthenia—Vincristine—lymphatic system cancer	0.000371	0.0016	CcSEcCtD
Estropipate—Diarrhoea—Carmustine—lymphatic system cancer	0.00037	0.0016	CcSEcCtD
Estropipate—Nausea—Bleomycin—lymphatic system cancer	0.000368	0.00159	CcSEcCtD
Estropipate—Asthenia—Mitoxantrone—lymphatic system cancer	0.000361	0.00156	CcSEcCtD
Estropipate—Dizziness—Carmustine—lymphatic system cancer	0.000358	0.00154	CcSEcCtD
Estropipate—Diarrhoea—Vincristine—lymphatic system cancer	0.000354	0.00152	CcSEcCtD
Estropipate—Pharyngitis—Methotrexate—lymphatic system cancer	0.00035	0.00151	CcSEcCtD
Estropipate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000344	0.00148	CcSEcCtD
Estropipate—Vomiting—Carmustine—lymphatic system cancer	0.000344	0.00148	CcSEcCtD
Estropipate—Dizziness—Vincristine—lymphatic system cancer	0.000342	0.00147	CcSEcCtD
Estropipate—Rash—Carmustine—lymphatic system cancer	0.000341	0.00147	CcSEcCtD
Estropipate—Dermatitis—Carmustine—lymphatic system cancer	0.000341	0.00147	CcSEcCtD
Estropipate—Visual impairment—Methotrexate—lymphatic system cancer	0.00034	0.00146	CcSEcCtD
Estropipate—Headache—Carmustine—lymphatic system cancer	0.000339	0.00146	CcSEcCtD
Estropipate—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000334	0.00144	CcSEcCtD
Estropipate—Eye disorder—Methotrexate—lymphatic system cancer	0.00033	0.00142	CcSEcCtD
Estropipate—Vomiting—Vincristine—lymphatic system cancer	0.000329	0.00142	CcSEcCtD
Estropipate—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000327	0.00141	CcSEcCtD
Estropipate—Rash—Vincristine—lymphatic system cancer	0.000326	0.0014	CcSEcCtD
Estropipate—Dermatitis—Vincristine—lymphatic system cancer	0.000325	0.0014	CcSEcCtD
Estropipate—Headache—Vincristine—lymphatic system cancer	0.000324	0.00139	CcSEcCtD
Estropipate—Nausea—Carmustine—lymphatic system cancer	0.000321	0.00138	CcSEcCtD
Estropipate—Angiopathy—Methotrexate—lymphatic system cancer	0.00032	0.00138	CcSEcCtD
Estropipate—Vomiting—Mitoxantrone—lymphatic system cancer	0.00032	0.00138	CcSEcCtD
Estropipate—Immune system disorder—Methotrexate—lymphatic system cancer	0.000319	0.00137	CcSEcCtD
Estropipate—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000318	0.00137	CcSEcCtD
Estropipate—Rash—Mitoxantrone—lymphatic system cancer	0.000317	0.00137	CcSEcCtD
Estropipate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000317	0.00137	CcSEcCtD
Estropipate—Headache—Mitoxantrone—lymphatic system cancer	0.000315	0.00136	CcSEcCtD
Estropipate—Alopecia—Methotrexate—lymphatic system cancer	0.000312	0.00134	CcSEcCtD
Estropipate—Mental disorder—Methotrexate—lymphatic system cancer	0.000309	0.00133	CcSEcCtD
Estropipate—Malnutrition—Methotrexate—lymphatic system cancer	0.000307	0.00132	CcSEcCtD
Estropipate—Erythema—Methotrexate—lymphatic system cancer	0.000307	0.00132	CcSEcCtD
Estropipate—Nausea—Vincristine—lymphatic system cancer	0.000307	0.00132	CcSEcCtD
Estropipate—Nausea—Mitoxantrone—lymphatic system cancer	0.000299	0.00129	CcSEcCtD
Estropipate—Back pain—Methotrexate—lymphatic system cancer	0.000297	0.00128	CcSEcCtD
Estropipate—Vertigo—Methotrexate—lymphatic system cancer	0.000276	0.00119	CcSEcCtD
Estropipate—Cough—Methotrexate—lymphatic system cancer	0.000268	0.00115	CcSEcCtD
Estropipate—Myalgia—Methotrexate—lymphatic system cancer	0.000262	0.00113	CcSEcCtD
Estropipate—Arthralgia—Methotrexate—lymphatic system cancer	0.000262	0.00113	CcSEcCtD
Estropipate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00026	0.00112	CcSEcCtD
Estropipate—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000251	0.00108	CcSEcCtD
Estropipate—Infection—Methotrexate—lymphatic system cancer	0.000249	0.00107	CcSEcCtD
Estropipate—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000246	0.00106	CcSEcCtD
Estropipate—Skin disorder—Methotrexate—lymphatic system cancer	0.000244	0.00105	CcSEcCtD
Estropipate—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000228	0.000984	CcSEcCtD
Estropipate—Insomnia—Methotrexate—lymphatic system cancer	0.000227	0.000977	CcSEcCtD
Estropipate—Paraesthesia—Methotrexate—lymphatic system cancer	0.000225	0.00097	CcSEcCtD
Estropipate—Somnolence—Methotrexate—lymphatic system cancer	0.000223	0.00096	CcSEcCtD
Estropipate—Dyspepsia—Methotrexate—lymphatic system cancer	0.000221	0.000951	CcSEcCtD
Estropipate—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000216	0.000932	CcSEcCtD
Estropipate—Fatigue—Methotrexate—lymphatic system cancer	0.000216	0.000931	CcSEcCtD
Estropipate—Pain—Methotrexate—lymphatic system cancer	0.000214	0.000923	CcSEcCtD
Estropipate—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000205	0.000883	CcSEcCtD
Estropipate—Urticaria—Methotrexate—lymphatic system cancer	0.000199	0.000858	CcSEcCtD
Estropipate—Abdominal pain—Methotrexate—lymphatic system cancer	0.000198	0.000854	CcSEcCtD
Estropipate—Body temperature increased—Methotrexate—lymphatic system cancer	0.000198	0.000854	CcSEcCtD
Estropipate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000185	0.000796	CcSEcCtD
Estropipate—Asthenia—Methotrexate—lymphatic system cancer	0.00018	0.000775	CcSEcCtD
Estropipate—Pruritus—Methotrexate—lymphatic system cancer	0.000177	0.000764	CcSEcCtD
Estropipate—Diarrhoea—Methotrexate—lymphatic system cancer	0.000172	0.000739	CcSEcCtD
Estropipate—Dizziness—Methotrexate—lymphatic system cancer	0.000166	0.000714	CcSEcCtD
Estropipate—Vomiting—Methotrexate—lymphatic system cancer	0.000159	0.000687	CcSEcCtD
Estropipate—Rash—Methotrexate—lymphatic system cancer	0.000158	0.000681	CcSEcCtD
Estropipate—Dermatitis—Methotrexate—lymphatic system cancer	0.000158	0.00068	CcSEcCtD
Estropipate—Headache—Methotrexate—lymphatic system cancer	0.000157	0.000677	CcSEcCtD
Estropipate—Nausea—Methotrexate—lymphatic system cancer	0.000149	0.000641	CcSEcCtD
